+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Migraine Drugs Market Research Report by Treatment Type, by Therapeutic Class, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968814
  • Report
  • July 2021
  • Region: Global
  • 184 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Migraine Drugs Market will Grow to USD 7,355.91 Million by 2026, at a CAGR of 15.64%

FEATURED COMPANIES

  • Aegis Therapeutics
  • Alder Biopharmaceuticals
  • Allergan
  • Eli Lilly
  • GlaxoSmithKline
  • Impax Laboratories
The Global Migraine Drugs Market size was estimated at USD 3,075.35 Million in 2020 and expected to reach USD 3,546.06 Million in 2021, at a Compound Annual Growth Rate (CAGR) 15.64% to reach USD 7,355.91 Million by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Migraine Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Treatment Type, the Migraine Drugs Market was studied across Abortive and Preventive.
  • Based on Route of Administration, the Migraine Drugs Market was studied across Injectable, Nasal Spray, and Oral.
  • Based on Therapeutic Class, the Migraine Drugs Market was studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
  • Based on Distribution, the Migraine Drugs Market was studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, the Migraine Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Migraine Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Migraine Drugs Market, including Aegis Therapeutics, Alder Biopharmaceuticals, Allergan, Eli Lilly, GlaxoSmithKline, Impax Laboratories, Johnson & Johnson, Luitpold Pharmaceuticals, Pfizer, TG Therapeutics, and Winston Pharmaceuticals.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Migraine Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Migraine Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Migraine Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Migraine Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Migraine Drugs Market?
6. What is the market share of the leading vendors in the Global Migraine Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Migraine Drugs Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aegis Therapeutics
  • Alder Biopharmaceuticals
  • Allergan
  • Eli Lilly
  • GlaxoSmithKline
  • Impax Laboratories
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Treatment Type Outlook
3.4. Route of Administration Outlook
3.5. Therapeutic Class Outlook
3.6. Distribution Outlook
3.7. Region Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of migraines and launch of new drugs
5.1.1.2. Rise in female population and increase in cigarette consumption
5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
5.1.2. Restraints
5.1.2.1. Side effects associated with migraine drugs
5.1.3. Opportunities
5.1.3.1. Supportive reimbursement policies for migraine medications
5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
5.1.4. Challenges
5.1.4.1. Availability of alternative therapies and regulatory challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Migraine Drugs Market, by Treatment Type
6.1. Introduction
6.2. Abortive
6.3. Preventive

7. Migraine Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.3. Nasal Spray
7.4. Oral

8. Migraine Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Anti-Nausea Drug
8.2.1. Chlorpromazine
8.2.2. Metoclopramide
8.2.3. Prochlorperazine
8.3. Blood Pressure Lowering Medication
8.3.1. Beta-Blocker
8.3.2. Calcium Channel Blocker
8.4. Ergots
8.4.1. Dihydroergotamines
8.4.2. Ergotamine
8.4.3. Lasmiditan
8.5. Opioid Medication
8.5.1. OxyContin
8.5.2. Percocet
8.5.3. Vicodin
8.6. Pain Reliever
8.6.1. Aspirin
8.6.2. Ibuprofen
8.7. Triptans
8.7.1. Rizatriptan
8.7.2. Sumatriptan

9. Migraine Drugs Market, by Distribution
9.1. Introduction
9.2. Hospitals Based Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy

10. Americas Migraine Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Migraine Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Thailand

12. Europe, Middle East & Africa Migraine Drugs Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Aegis Therapeutics
14.2. Alder Biopharmaceuticals
14.3. Allergan
14.4. Eli Lilly
14.5. GlaxoSmithKline
14.6. Impax Laboratories
14.7. Johnson & Johnson
14.8. Luitpold Pharmaceuticals
14.9. Pfizer
14.10. TG Therapeutics
14.11. Winston Pharmaceuticals

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2020 (USD MILLION)
FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2020 (USD MILLION)
FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET: MARKET DYNAMICS
FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2020 VS 2026 (%)
FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2026
FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (%)
FIGURE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2026 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2026
FIGURE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2026 (USD MILLION)
FIGURE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (%)
FIGURE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2026
FIGURE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2026 (USD MILLION)
FIGURE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, 2018-2026 (USD MILLION)
FIGURE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, 2018-2026 (USD MILLION)
FIGURE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, 2018-2026 (USD MILLION)
FIGURE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2026 (USD MILLION)
FIGURE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, 2018-2026 (USD MILLION)
FIGURE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2018-2026 (USD MILLION)
FIGURE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2026 (USD MILLION)
FIGURE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, 2018-2026 (USD MILLION)
FIGURE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, 2018-2026 (USD MILLION)
FIGURE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, 2018-2026 (USD MILLION)
FIGURE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2026 (USD MILLION)
FIGURE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, 2018-2026 (USD MILLION)
FIGURE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, 2018-2026 (USD MILLION)
FIGURE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, 2018-2026 (USD MILLION)
FIGURE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2026 (USD MILLION)
FIGURE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, 2018-2026 (USD MILLION)
FIGURE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, 2018-2026 (USD MILLION)
FIGURE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 65. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2026 (USD MILLION)
FIGURE 66. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 67. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, 2018-2026 (USD MILLION)
FIGURE 68. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 69. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, 2018-2026 (USD MILLION)
FIGURE 70. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 71. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 72. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD MILLION)
FIGURE 73. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 74. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, 2018-2026 (USD MILLION)
FIGURE 75. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 76. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD MILLION)
FIGURE 77. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD MILLION)
FIGURE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 80. AMERICAS MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 81. ARGENTINA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 82. BRAZIL MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 83. CANADA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 84. MEXICO MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 85. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 86. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 87. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 88. CHINA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 89. INDIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 90. INDONESIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 91. JAPAN MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 92. MALAYSIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 93. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 94. SINGAPORE MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 95. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 96. THAILAND MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 97. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 98. FRANCE MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 99. GERMANY MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 100. ITALY MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 101. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 102. QATAR MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 103. RUSSIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 104. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 105. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 106. SPAIN MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 107. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 108. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 109. GLOBAL MIGRAINE DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 110. GLOBAL MIGRAINE DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 111. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MIGRAINE DRUGS MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL MIGRAINE DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2026 (USD MILLION)
TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2026 (USD MILLION)
TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2026 (USD MILLION)
TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2026 (USD MILLION)
TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2026 (USD MILLION)
TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2026 (USD MILLION)
TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2026 (USD MILLION)
TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2026 (USD MILLION)
TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2026 (USD MILLION)
TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2026 (USD MILLION)
TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2026 (USD MILLION)
TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2026 (USD MILLION)
TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2026 (USD MILLION)
TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2026 (USD MILLION)
TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD MILLION)
TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2026 (USD MILLION)
TABLE 37. AMERICAS MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. ARGENTINA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. BRAZIL MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. CANADA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. MEXICO MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 44. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 45. CHINA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 46. INDIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 47. INDONESIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 48. JAPAN MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 49. MALAYSIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 50. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 51. SINGAPORE MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 52. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 53. THAILAND MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 55. FRANCE MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 56. GERMANY MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 57. ITALY MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 58. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 59. QATAR MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 60. RUSSIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 61. SAUDI ARABIA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 62. SOUTH AFRICA MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 63. SPAIN MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 64. UNITED ARAB EMIRATES MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 65. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 66. GLOBAL MIGRAINE DRUGS MARKET: SCORES
TABLE 67. GLOBAL MIGRAINE DRUGS MARKET: BUSINESS STRATEGY
TABLE 68. GLOBAL MIGRAINE DRUGS MARKET: PRODUCT SATISFACTION
TABLE 69. GLOBAL MIGRAINE DRUGS MARKET: RANKING
TABLE 70. GLOBAL MIGRAINE DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 71. GLOBAL MIGRAINE DRUGS MARKET: MERGER & ACQUISITION
TABLE 72. GLOBAL MIGRAINE DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 73. GLOBAL MIGRAINE DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 74. GLOBAL MIGRAINE DRUGS MARKET: INVESTMENT & FUNDING
TABLE 75. GLOBAL MIGRAINE DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 76. GLOBAL MIGRAINE DRUGS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Aegis Therapeutics
  • Alder Biopharmaceuticals
  • Allergan
  • Eli Lilly
  • GlaxoSmithKline
  • Impax Laboratories
  • Johnson & Johnson
  • Luitpold Pharmaceuticals
  • Pfizer
  • TG Therapeutics
  • Winston Pharmaceuticals
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll